Last reviewed · How we verify
ASP3652
ASP3652 is a selective antagonist of the complement C5a receptor that inhibits complement-mediated inflammation.
ASP3652 is a selective antagonist of the complement C5a receptor that inhibits complement-mediated inflammation. Used for Complement-mediated inflammatory disorders (Phase 2 development).
At a glance
| Generic name | ASP3652 |
|---|---|
| Sponsor | Astellas Pharma Europe B.V. |
| Drug class | C5a receptor antagonist |
| Target | C5a receptor (C5aR) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
ASP3652 blocks the C5a receptor on immune cells, preventing the recruitment and activation of neutrophils and other inflammatory cells downstream of complement cascade activation. This mechanism reduces tissue damage and inflammation in complement-driven diseases. The drug is designed to provide targeted anti-inflammatory effects while preserving other immune functions.
Approved indications
- Complement-mediated inflammatory disorders (Phase 2 development)
Common side effects
Key clinical trials
- A Randomized Study Comparing Placebo and ASP3652 in the Treatment of Women With Bladder Pain Syndrome / Interstitial Cystitis (BPS/IC) (PHASE2)
- A Study to Assess the Safety, Tolerability, and Effects in and on the Body of Healthy Young and Elderly Male and Female Subjects of Ascending Multiple Oral Doses of ASP3652 (PHASE1)
- A Study to Assess the Pharmacokinetics, Metabolism and Excretion Routes of ASP3652 in Man, After Administration of 14C Radio Labeled ASP3652 (PHASE1)
- A Study to Investigate the Appearance and Disappearance of ASP3652 in Blood and Spinal Fluid in Healthy Male Subjects (PHASE1)
- A Study to Assess the Effect of Race on How a Single Dose of ASP3652 is Taken up, Metabolized and Distributed Through the Bodies of Young, Healthy Male and Female Subjects, and Its Safety and Tolerability (PHASE1)
- A Clinical Study to Investigate the Efficacy, Safety and Pharmacokinetics of ASP3652 in Patients With Chronic Abacterial Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS) (PHASE2)
- A Study to Assess the Safety, Tolerability and Effects of Single Ascending Doses of ASP3652 in Healthy Subjects (PHASE1)
- A Study to Assess the Effect of Multiple Doses of Gemfribozil on a Single Dose of ASP3652, and to Assess the Effects of Multiple Doses of ASP3652 on a Single Dose of Repaglinide in the Body of Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ASP3652 CI brief — competitive landscape report
- ASP3652 updates RSS · CI watch RSS
- Astellas Pharma Europe B.V. portfolio CI